10-Q quarterly report · filed Nov 4, 2026

ADMA BIOLOGICS, INC. (ADMA) Q3 2026 10-Q Quarterly Report

Short answer

ADMA BIOLOGICS, INC. (ADMA) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $141M (up 5.1% year over year) with net income of $50M.

Q3 2026 key financials · XBRL

Revenue
$141M
+5.1% YoY · +13.4% QoQ
Net income
$50M
+36.9% YoY · +31.9% QoQ
Operating margin
48.0%
Gross margin
70.8%
EPS (diluted)
$0.22
+46.7% YoY · +37.5% QoQ

Source: XBRL data from the ADMA BIOLOGICS, INC. (ADMA) Q3 2026 10-Q on SEC EDGAR. USD.

ADMA BIOLOGICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $141.1M, up 5.1% YoY from $134.2M
  • Gross margin 70.8% vs 56.3% YoY, net income $49.9M vs $36.4M
  • Best performer ASCENIV revenue $124.7M, up 30.7%; BIVIGAM worst, $15.4M, down 35.2%
  • Cash $124.6M vs $87.6M at December 31, 2025; nine-month operating cash flow $105.2M vs $14.8M
  • Competitive IVIG pricing pressured BIVIGAM; inflation and supply-chain costs expected through Q4 2026 and 2027

Risk Factors

  • Newly added securities litigation risk: July 10, 2026 class action and consolidated derivative proceedings alleging Exchange Act violations
  • Most materially updated competitive risk: new FDA-approved IVIG competitors since 2H 2025 using aggressive pricing, rebates and extended payment terms
  • Regulatory risk: FDA inspections could trigger warning letters, recalls, supply disruptions or manufacturing restrictions for ADMA and suppliers
  • Operational risk: high-titer RSV plasma meeting specifications represents less than 10% of tested donor samples
  • Financial risk: $197.2 million JPMorgan debt outstanding, maturing August 5, 2028, with substantially all assets pledged as collateral

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ADMA BIOLOGICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.